miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting by Yilan Xu, Danyang Li, Na Wang, Bei Ge, Chen Meng, Min Zhao, Zihan Lin, Min Li, Yigang Yuan, Yue Cai, Liuzhi Shi, Shenmeng Gao, Haige Ye

“…Abstract Background 5-Azacytidine (AZA) combined with the BCL2 inhibitor Venetoclax (VEN) is the standard treatment for elderly acute myeloid leukemia (AML) patients or those who are unfit for intensive chemotherapy (elderly or unfit AML). However, an effective and rapid predictive biomarker to predict treatment outcome remains elusive. …”
Get full text

Early tolerance and late persistence as alternative drug responses in cancer by Simona Punzi, Davide Cittaro, Guido Gatti, Gemma Crupi, Oronza A. Botrugno, Antonino Alex Cartalemi, Alon Gutfreund, Caterina Oneto, Valentina Giansanti, Chiara Battistini, Giovanni Santacatterina, Lucrezia Patruno, Ilaria Villanti, Martina Palumbo, Daniel J. Laverty, Francesca Giannese, Alex Graudenzi, Giulio Caravagna, Marco Antoniotti, Zachary Nagel, Ugo Cavallaro, Luisa Lanfrancone, Timothy A. Yap, Giulio Draetta, Nathalie Balaban, Giovanni Tonon

“…Here, we show that human cancer cells elicit a tolerant response when exposed to commonly used chemotherapy regimens, propelled by the pervasive activation of autophagy, leading to the comprehensive activation of DNA damage repair pathways. …”
Get full text

Oncological outcomes following extreme oncoplastic breast conserving surgery (eOPBCS) for locally advanced breast cancer (LABC): A systematic review and meta-analysis by Megan Chua Wern Ee, Ashley Lee Shi Hui, Wong Hung Chew, Emmeline Elaine Cua-Delos Santos, Sean Li Siwei, Sng Ming Xian, Qin Xiang Ng, Serene Goh Si Ning

“…Advances in neoadjuvant chemotherapy (NACT), breast-conserving surgery (BCS), and radiation have transformed treatment into a multimodal approach. …”
Get full text

Race as a prognostic factor of breast mucinous carcinoma by Dingyuan Wang, Yang Wang, Songlin Gao, Rongshou Zheng, Guijian Wu, Jianping Wang, Can Lu, Kena Bu, Chun Zhang, Wanqing Chen, Bailin Zhang

“…Specifically, non-Chinese American patients had a worse OS compared to Chinese patients (adjusted HR = 2.59, 95% CI: 1.15–5.83, P = 0.022). Chemotherapy significantly improved OS only in black BMC patients (adjusted HR = 0.52, 95% CI: 0.27–0.98, p = 0.045), but not in other racial/ethnic groups. …”
Get full text

Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Ph... by Su H, Shang X, Liu H, Wang Y, Yu Y, Xu Y, Jiang K, Feng F

“…PROC patients with multiple recurrences are unable to continue highly toxic treatment after prior multiple lines of systemic therapy. Chemotherapy-free option lenvatinib plus anti-programmed cell death protein-1 (PD-1) combination therapy has shown promising results in several malignancies including ovarian cancer, but the toxicity of a high starting dose of lenvatinib is also notable and needs to be improved. …”
Get full text

The INFLUENCE 3.0 model: Updated predictions of locoregional recurrence and contralateral breast cancer, now also suitable for patients treated with neoadjuvant systemic therapy by M.C. Van Maaren, T.A. Hueting, D.J.P. van Uden, M. van Hezewijk, L. de Munck, M.A.M. Mureau, P.A. Seegers, Q.J.M. Voorham, M.K. Schmidt, G.S. Sonke, C.G.M. Groothuis-Oudshoorn, S. Siesling

“…Age, mode of detection, histology, sublocalisation, grade, pT, pN, hormonal receptor status ± endocrine treatment, HER2 status ± targeted treatment, surgery ± immediate reconstruction ± radiation therapy, and chemotherapy were significant predictors for LRR and/or CBC in non-NST patients. …”
Get full text

Treatment of autonomous intestinal neuropathy in critical care by prucalopride and multistrain probiotic by A. L. Kovaleva, A. I. Ulyanin, O. Yu. Kiselyova, Ye. A. Poluektova, O. S. Shifrin, A. S. Tertychny, V. T. Ivashkin

“…According to the past history in 2014 patient was diagnosed to have adenocarcinoma of the right breast gland with subsequent right-sided radical mastectomy followed by radiation therapy and chemotherapy. In May 2017 patient developed boring pain in the right lumbar area, frequent small-volume urination, febrile fever and progressive general weakness. …”
Get full text

Phase II clinical trial assessing the addition of hyperthermia to salvage concurrent chemoradiotherapy for unresectable recurrent head and neck cancer in previously irradiated pati... by Kai-Lin Yang, Mau-Shin Chi, Chung-Yu Hao, Hui-Ling Ko, Yi-Ying Huang, Ren-Hong Wu, Hung-Chih Lai, Ying-Chu Lin, Sheng-Po Hao, Kwan-Hwa Chi

“…Weekly hyperthermia for 6 sessions started after RT initiation; each session lasted for 40 min, beginning within 2 h after RT and maintaining a maximum temperature of 42 ± 0.5 °C. Concurrent chemotherapy included weekly cisplatin 20 mg/m2 and docetaxel 10–12 mg/m2 for 6 weeks. …”
Get full text

Outbreak of carbapenem resistant Klebsiella pneumoniae in a neurorehabilitation unit: Genomic epidemiology reveals complex transmission pattern in a tertiary care hospital by Maria Grazia Silvotti, Erika Scaltriti, Luca Bolzoni, Beatrice Zerbi, Gabriella Tocci, Andrea Zappavigna, Gianfranco Lamberti, Federico Donati, Franco Federici, Stefano Pongolini, Giuliana Lo Cascio

“…Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.…”
Get full text

Clinical Characteristics and Optimization of Empirical Antimicrobial Therapy for Febrile Neutropenia in Patients With Hematologic Malignancies by Cui Y, Liu X, Feng S

“…These findings underscore the need for updated clinical guidelines that address evolving pathogen profiles and the growing challenge of MDR infections.Summary: Infection-related complications remain a leading cause of mortality in HM patients, often limiting the implementation of chemotherapy. Early and appropriate empirical therapy significantly improves outcomes in FN, reducing hospital stays and healthcare costs. …”
Get full text

Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment incl... by Hidekazu Hirano, Naoki Takahashi, Yusuke Amanuma, Nobumi Suzuki, Daisuke Takahari, Takeshi Kawakami, Chie Kudo-Saito, Kengo Nagashima, Narikazu Boku, Ken Kato, Hirokazu Shoji

“…Accumulating evidence suggests rationales for continuing immunotherapy beyond progression, synergistic effects between immune checkpoint inhibitors and angiogenesis inhibitors, and a preferable combination of steroid-free chemotherapy with immunotherapy. These rationales imply that nanoparticle albumin-bound (nab)-paclitaxel plus ramucirumab in combination with nivolumab (anti-PD-1 antibody) may enhance anti-tumor effects as second-line treatment. …”
Get full text

In vitro antitumor and immunomodulatory activities of 1,2,4-oxadiazole derivatives by Héverton Mendes Araújo, Gabriel Acácio de Moura, Yasmim Mendes Rocha, Cristian Vicson Pinheiro Gomes, Valentina Nascimento e Melo de Oliveira, Ronaldo Nascimento de Oliveira, Larissa Deadame de Figueiredo Nicolete, Emanuel Paula Magalhães, Ramon R.P.P.B. de Menezes, Roberto Nicolete

“…However, for more advanced cases with a high recurrence rate, the preferred approach is to combine chemotherapy with immunotherapy treatments. Tumor-associated macrophages (TAMs) are the most abundant leukocytes in solid tumors. …”
Get full text

Protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials by José Pinto-Fraga, Celia García-Chico, Simone Lista, Pedro Miguel Lacal, Giuseppe Carpenzano, Maurizio Salvati, Alejandro Santos-Lozano, Grazia Graziani, Claudia Ceci

“…The standard treatment for newly diagnosed GBM includes surgical resection, when feasible, followed by radiotherapy and temozolomide-based chemotherapy. Upon disease progression, the anti-vascular endothelial growth factor-A (VEGF-A) monoclonal antibody bevacizumab, can be considered.Given the limited efficacy of pharmacological treatments, particularly for the recurrent disease, several molecularly targeted interventions have been explored, such as small-molecule protein kinase inhibitors (PKIs), inhibiting tyrosine kinase growth factor receptors and downstream signaling pathways involved in GBM angiogenesis and infiltrative behavior.This meta-analysis, based on searches in PubMed and Web Of Science, evaluated 12 randomized controlled trials (RCTs) examining PKIs in patients with newly diagnosed or recurrent GBM. …”
Get full text

IFN-γ reprograms cardiac microvascular endothelial cells to mediate doxorubicin transport and influences the sensitivity of mice to doxorubicin-induced cardiotoxicity by Haoyu Ji, Wenya Ma, Xu Liu, Hongyang Chen, Yining Liu, Zhongyu Ren, Daohong Yin, Ao Cai, Zizhen Zhang, Xin Wang, Wei Huang, Leping Shi, Yanan Tian, Yang Yu, Xiuxiu Wang, Yang Li, Yu Liu, Benzhi Cai

“…Abstract Doxorubicin (DOX) is a first-line chemotherapy agent known for its cardiac toxicity. DOX-induced cardiotoxicity (DIC) severely limits the use for treating malignant tumors and is associated with a poor prognosis. …”
Get full text

Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50% by Yoshihito Kogure, MD, PhD, Hiroya Hashimoto, PhD, Haruko Daga, MD, PhD, Yasushi Fukuda, MD, Akihiro Bessho, MD, PhD, Tadaaki Yamada, MD, PhD, Yukihiro Toi, MD, Tomoki Kimura, MD, PhD, Hiroshige Yoshioka, MD, PhD, Koichi Azuma, MD, PhD, Naoki Furuya, MD, PhD, Yasutaka Fukui, MD, PhD, Akiko M. Saito, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Hideo Saka, MD, Masashi Kondo, MD, PhD

“…Eligible participants had metastatic or recurrent nonsquamous NSCLC without sensitizing EGFR or ALK alterations, were aged 75 years or above, had a programmed cell death-ligand 1 tumor proportion score of less than 50%, had not undergone systemic chemotherapy, and had an Eastern Cooperative Oncology Group performance status of 0 or 1. …”
Get full text

Shaoyao Gancao decoction alleviates paclitaxel-induced cognitive impairment by activating PTEN/PI3K/AKT pathway to inhibit NETs formation by Xu Ying, Su Yue, Hu Yuwen, Li Xiang, Zhou Ziyan, Yuan Ningning, Ji Xiaowei, Jiang Ruoyu, Wang Wenzhu, Zhang Yafeng, Zhai Guojie, Cheng Xiaolan

“…Purpose: Paclitaxel-induced cognitive impairment (PICI) is a frequent and severe adverse reaction of chemotherapy. Increased neuroinflammation related to neutrophil extracellular traps (NETs) may play a key role in PICI. …”
Get full text

Treatment of Helicobacter pylori infection: mainstream and innovations (Review of the literature and Russian gastroenterological association Advisory council resolution, May 19, 20... by V. T. Ivashkin, I. V. Mayev, T. L. Lapina, A. A. Sheptulin, A. S. Trukhmanov, R. A. Abdulkhakov, S. A. Alekseyenko, N. N. Dekhnich, R. S. Kozlov, I. L. Klyaritskaya, S. A. Kurilovich, M. F. Osipenko, V. I. Simanenkov, I. B. Khlynov

Get full text

Collagen turnover biomarkers to predict outcome of patients with biliary cancer by Leonard Kaps, Muhammed A. Genc, Markus Moehler, Stephan Grabbe, Jörn M. Schattenberg, Detlef Schuppan, Rasmus Sund Pedersen, Morten A. Karsdal, Philipp Mildenberger, Annett Maderer, Nicholas Willumsen

“…Methods We measured the seven biomarkers of collagen turnover in sera of 72 patients with BTC at baseline and after first and second chemotherapy cycle (CTX). Markers were also assessed in sera of 50 healthy controls and compared to levels of patients at baseline. …”
Get full text

L-glutaminase synthesis by Klebsiella pneumoniae (AS KP 23) isolated from clinical strain, and its efficacy against human hepatocellular and breast cancer cell lines by Lina J. Abdel-Hafez, Eman Y. T. Elariny, Asmaa E. Ibrahim, Mahmoud E. F. Abdel-Haliem

“…L-glutaminase has been cited as the most potent molecule that inhibits the proliferation of cancer cells, which significantly raises the possible applicability of cancer therapy and the possibility of its application as an alternative drug to chemotherapy. The first investigation into the antitumor property of L-glutaminase revealed its inhibitory effect on the growth of Gardner lymphosarcoma (6C3HED) and L-1210 leukemia cells. …”
Get full text

Gut microbiota derived DCA enhances FOLFOX efficacy via Ugt1a6b mediated enterohepatic circulation in colon cancer by Qian Fang, Xiaoying Hou, Limei Fan, Yufei Deng, Xiaoxuan Li, Hongyun Zhang, Haiping Wang, Zhengqi Fu, Binlian Sun, Xiji Shu, Hongzhi Du, Yuchen Liu

“…FOLFOX (5-Fluorouracil, Calcium Folinate combined with Oxaliplatin) is a preferred chemotherapy regimen for colon cancer, but its limited efficacy remains a major challenge, significantly impairs patient outcomes. …”
Get full text